Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8723937 | PMC |
| http://dx.doi.org/10.1212/CPJ.0000000000001026 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Danaparoid-Consensus Recommendations on Its Clinical Use.
Pharmaceuticals (Basel)
November 2024
Independent Researcher, 5345 MT Oss, The Netherlands.
(1) Background: Danaparoid sodium is a heparinoid antithrombotic that has been used for over 40 years for prophylaxis of DVT in non-HIT patients and for the treatment of heparin-induced thrombocytopenia (HIT) with and without thrombosis. This update summarises current information on its pharmacology and reviews danaparoid dose management in a broad spectrum of clinical situations, including off-label indications. (2) Methods: Evidence from published clinical studies, case reports, compassionate use of danaparoid, and spontaneously reported serious adverse events is summarised and analysed by an interdisciplinary expert group to develop a consensus on dosing regimens of danaparoid for complex clinical situations, including vulnerable patient populations.
View Article and Find Full Text PDFA hemoadhican-based sponge with anti-heparin interference for treating uncontrollable massive hemorrhage.
Int J Biol Macromol
November 2024
Center for Molecular Metabolism, Nanjing University of Science & Technology, Nanjing, 210094, China; Key laboratory of Metabolic Engineering and Biosynthesis Technology, Ministry of Industry and Information Technology, 210094, China. Electronic address:
Hemoadhican (HD) is an exopolysaccharide with a branched structure that has been reported for its high hemostatic ability. In this study, a HD-based hemostatic sponge was prepared through ultrasonic dissolution and freeze-drying without using any cross-linking agent. The sponge could spontaneously cross-link using hydrogen bonds to form adhesive mud within 3 s upon contact with blood.
View Article and Find Full Text PDFA disproportionality analysis of low molecular weight heparin in the overall population and in pregnancy women using the FDA adverse event reporting system (FAERS) database.
Front Pharmacol
August 2024
Foshan Clinical Medical School of Guangzhou University of Chinese Medicine, Foshan, Guangdong, China.
Article Synopsis
- The study investigates adverse events (AEs) linked to low molecular weight heparin (LMWH), particularly focusing on its use in the general population and pregnant women, using the FDA Adverse Event Reporting System.
- Various analytical methods were utilized, including reporting odds ratios and Bayesian approaches, to identify significant AE signals associated with LMWH.
- Key findings revealed several notable AEs for both the overall population (e.g., anti factor X antibody positive) and pregnant women (e.g., sternal fracture), highlighting the need for more attention to the adverse effects of LMWH in clinical settings.
Anti-platelet factor 4 immunothrombotic syndromes.
Br J Haematol
October 2024
Department of Haematology, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
Anti-platelet factor 4 immunothrombotic syndromes comprise a group of disorders that include heparin-induced thrombocytopenia and vaccine-induced immune thrombocytopenia and thrombosis. These are highly prothrombotic, immunological disorders characterised by specific clinical and pathological criteria which include thrombocytopenia and thrombosis. While they are predominantly triggered by heparin and the adenoviral vector vaccines, respectively, other provoking factors have been described, as well as spontaneous forms.
View Article and Find Full Text PDFA Case Report of Pulmonary Embolectomy Under Cardiopulmonary Bypass in a Patient with Intracranial Hemorrhage and History of Heparin-Induced Thrombocytopenia.
A A Pract
April 2024
From the Departments of Department of Anaesthesia and Critical Care, Angers University Hospital, Angers, France.
Pulmonary embolism is a common complication after intracranial hemorrhage. As thrombolysis is contraindicated in this situation, surgical pulmonary embolectomy may be indicated in case of high-risk pulmonary embolism but requires transient anticoagulation with heparin during cardiopulmonary bypass. We report the case of a patient with a history of heparin-induced thrombocytopenia who presented with a high-risk pulmonary embolism 10 days after the spontaneous onset of a voluminous intracerebral hematoma.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!